Mesoblast Revenue Soars to $120M on RYONCIL Growth
Event summary
- Mesoblast reported $120.3M in total revenue for FY2026, up from $17.2M in the prior year, driven by RYONCIL's commercial launch.
- RYONCIL generated $115.2M in net revenue after a 13.4% gross-to-net adjustment, with broad payer coverage across 280M lives.
- Phase 3 trial for rexlemestrocel-L in chronic low back pain completed treatment, with top-line results expected in mid-2027.
- Company secured a $125M five-year credit-line facility, retiring higher-cost facilities, and ended the period with $103M in cash.
The big picture
Mesoblast's substantial revenue growth underscores the success of its RYONCIL launch and the expanding market for cellular medicines in inflammatory diseases. The completion of the Phase 3 trial for rexlemestrocel-L positions the company for a potential blockbuster opportunity in chronic low back pain, a market with significant unmet needs. The strategic shift to target larger patient populations, including adults with SR-aGvHD, highlights Mesoblast's focus on scaling its commercial footprint.
What we're watching
- Market Expansion
- Whether Mesoblast can successfully expand RYONCIL's label to adults with SR-aGvHD and children with Duchenne muscular dystrophy.
- Clinical Outcomes
- The impact of the Phase 3 trial results for rexlemestrocel-L in chronic low back pain on the potential multi-billion-dollar market opportunity.
- Financial Discipline
- How Mesoblast balances continued R&D investment with disciplined capital allocation to sustain growth.
Related topics